{'fraction_non_alphanumeric': 0.022099447513812154, 'fraction_numerical': 0.0011049723756906078, 'mean_word_length': 5.121621621621622, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 1, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Developing granulocyte-colony stimulating factor for the treatment of stroke: current status of clinical trials.

To the Editor:

The review of Solaroglu et al1 on granulocyte-colony stimulating factor (G-CSF) as novel neuroprotectant is important, and the fact that it comes from a group not involved in primary research in this field illustrates the growing attention of the general stroke community to hematopoietic factors for the treatment of stroke. However, we believe that the readers of Stroke would also be highly interested in recent clinical developments in this field, which are not mentioned in the article. We have, therefore, summarized the currently ongoing G-CSF trials in stroke.

Preclinical studies clearly demonstrated activity of G-CSF in the acute as well as in the chronic stroke situation and suggest therapeutic potential in both settings. The powerful multimodal interference …